These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 27769114)

  • 41. NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancers.
    Oshima Y; Shimada H; Yajima S; Nanami T; Matsushita K; Nomura F; Kainuma O; Takiguchi N; Soda H; Ueda T; Iizasa T; Yamamoto N; Yamamoto H; Nagata M; Yokoi S; Tagawa M; Ohtsuka S; Kuwajima A; Murakami A; Kaneko H
    J Gastroenterol; 2016 Jan; 51(1):30-4. PubMed ID: 25906289
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients.
    Wu C; Hao H; Li L; Zhou X; Guo Z; Zhang L; Zhang X; Zhong W; Guo H; Bremner RM; Lin P
    J Thorac Oncol; 2009 Jan; 4(1):30-6. PubMed ID: 19096303
    [TBL] [Abstract][Full Text] [Related]  

  • 43. ADAM28 is a serological and histochemical marker for non-small-cell lung cancers.
    Kuroda H; Mochizuki S; Shimoda M; Chijiiwa M; Kamiya K; Izumi Y; Watanabe M; Horinouchi H; Kawamura M; Kobayashi K; Okada Y
    Int J Cancer; 2010 Oct; 127(8):1844-56. PubMed ID: 20112342
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Autoantibodies: Potential clinical applications in early detection of esophageal squamous cell carcinoma and esophagogastric junction adenocarcinoma.
    Xu YW; Peng YH; Xu LY; Xie JJ; Li EM
    World J Gastroenterol; 2019 Sep; 25(34):5049-5068. PubMed ID: 31558856
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sequential screening for lung cancer in a high-risk group: randomised controlled trial: LungSEARCH: a randomised controlled trial of Surveillance using sputum and imaging for the EARly detection of lung Cancer in a High-risk group.
    Spiro SG; Shah PL; Rintoul RC; George J; Janes S; Callister M; Novelli M; Shaw P; Kocjan G; Griffiths C; Falzon M; Booton R; Magee N; Peake M; Dhillon P; Sridharan K; Nicholson AG; Padley S; Taylor MN; Ahmed A; Allen J; Ngai Y; Chinyanganya N; Ashford-Turner V; Lewis S; Oukrif D; Rabbitts P; Counsell N; Hackshaw A
    Eur Respir J; 2019 Oct; 54(4):. PubMed ID: 31537697
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Early detection of NSCLC with scFv selected against IgM autoantibody.
    Pedchenko T; Mernaugh R; Parekh D; Li M; Massion PP
    PLoS One; 2013; 8(4):e60934. PubMed ID: 23585862
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Application of serum NY-ESO-1 antibody assay for early SCLC diagnosis.
    Yang J; Jiao S; Kang J; Li R; Zhang G
    Int J Clin Exp Pathol; 2015; 8(11):14959-64. PubMed ID: 26823828
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The role of extended cervical mediastinoscopy in staging of non-small cell lung cancer of the left lung and a comparison with integrated positron emission tomography and computed tomography: does integrated positron emission tomography and computed tomography reduce the need for invasive procedures?
    Metin M; Citak N; Sayar A; Pekcolaklar A; Melek H; Kök A; Gurses A
    J Thorac Oncol; 2011 Oct; 6(10):1713-9. PubMed ID: 21716145
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Autoantibodies: Opportunities for Early Cancer Detection.
    Macdonald IK; Parsy-Kowalska CB; Chapman CJ
    Trends Cancer; 2017 Mar; 3(3):198-213. PubMed ID: 28718432
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial.
    Darling GE; Maziak DE; Inculet RI; Gulenchyn KY; Driedger AA; Ung YC; Gu CS; Kuruvilla MS; Cline KJ; Julian JA; Evans WK; Levine MN
    J Thorac Oncol; 2011 Aug; 6(8):1367-72. PubMed ID: 21587082
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Untangling the evolutionary roots of lung cancer.
    Devarakonda S; Govindan R
    Nat Commun; 2019 Jul; 10(1):2979. PubMed ID: 31278259
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Danish randomized lung cancer CT screening trial--overall design and results of the prevalence round.
    Pedersen JH; Ashraf H; Dirksen A; Bach K; Hansen H; Toennesen P; Thorsen H; Brodersen J; Skov BG; Døssing M; Mortensen J; Richter K; Clementsen P; Seersholm N
    J Thorac Oncol; 2009 May; 4(5):608-14. PubMed ID: 19357536
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combined detection of serum autoantibodies as diagnostic biomarkers in esophagogastric junction adenocarcinoma.
    Xu YW; Chen H; Guo HP; Yang SH; Luo YH; Liu CT; Huang XY; Tang XM; Hong CQ; Li EM; Xu LY; Peng YH
    Gastric Cancer; 2019 May; 22(3):546-557. PubMed ID: 30426295
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Comparing serum tumor antigen detection combined with CT scan with PET-CT for lung cancer diagnosis].
    Zhang X; Li TR; Chen ZS; Ouyang XN
    Ai Zheng; 2006 Jan; 25(1):66-8. PubMed ID: 16405752
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Blood autoantibodies against tumor-associated antigens as biomarkers in early detection of colorectal cancer.
    Chen H; Werner S; Tao S; Zörnig I; Brenner H
    Cancer Lett; 2014 May; 346(2):178-87. PubMed ID: 24462820
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Squamous cell carcinoma antigen in lung cancer and nonmalignant respiratory diseases.
    Kagohashi K; Satoh H; Kurishima K; Kadono K; Ishikawa H; Ohtsuka M; Sekizawa K
    Lung; 2008; 186(5):323-6. PubMed ID: 18663529
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prospective evaluation of 64 serum autoantibodies as biomarkers for early detection of colorectal cancer in a true screening setting.
    Chen H; Werner S; Butt J; Zörnig I; Knebel P; Michel A; Eichmüller SB; Jäger D; Waterboer T; Pawlita M; Brenner H
    Oncotarget; 2016 Mar; 7(13):16420-32. PubMed ID: 26909861
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of serum miRNAs by nano-quantum dots microarray as diagnostic biomarkers for early detection of non-small cell lung cancer.
    Fan L; Qi H; Teng J; Su B; Chen H; Wang C; Xia Q
    Tumour Biol; 2016 Jun; 37(6):7777-84. PubMed ID: 26695145
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antineural and antinuclear autoantibodies are of prognostic relevance in non-small cell lung cancer.
    Blaes F; Klotz M; Huwer H; Straub U; Kalweit G; Schimrigk K; Schäfers HJ
    Ann Thorac Surg; 2000 Jan; 69(1):254-8. PubMed ID: 10654525
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serum proteomic profiling of lung cancer in high-risk groups and determination of clinical outcomes.
    Jacot W; Lhermitte L; Dossat N; Pujol JL; Molinari N; Daurès JP; Maudelonde T; Mangé A; Solassol J
    J Thorac Oncol; 2008 Aug; 3(8):840-50. PubMed ID: 18670301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.